- /
- Supported exchanges
- / MU
- / D4S.MU
Daiichi Sankyo Company Limited (D4S MU) stock market data APIs
Daiichi Sankyo Company Limited Financial Data Overview
There is no Profile data available for D4S.MU.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Daiichi Sankyo Company Limited data using free add-ons & libraries
Get Daiichi Sankyo Company Limited Fundamental Data
Daiichi Sankyo Company Limited Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Daiichi Sankyo Company Limited Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-10-30
- EPS/Forecast: 43.91
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Daiichi Sankyo Company Limited News
New
Will Cancer Drug Delivery Partnership Change Daiichi Sankyo Stock Narrative
Daiichi Sankyo and iDEL Therapeutics entered a multi year global research collaboration to test a new multi drug conjugate platform for targeted delivery into solid tumor cells, assessing it against a...
iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells
iDEL Therapeutics GmbH — Collaboration's objective is to evaluate the potential of a cancer therapeutic by using iDEL's unique shuttle technology platform — Dortmund, Germany, November 09, 2026 ...
Antibody-Drug Conjugates (ADC) Market Size, Share, Trends, and Global Forecast to 2036 | Market Set to Reach $74.15 Billion at 13.5% CAGR as Next-Generation ADCs and Asia-Pacific Drive Growth
Company Logo Dublin, Nov. 05, 2026 (GLOBE NEWSWIRE) -- "Antibody-Drug Conjugates (ADC) Market Size, Share, and Industry Analysis - Global Forecast to 2036" has been added to ResearchAndMarkets.com's ...
Enhertu® Wins 2026 International Prix Galien Award for Best Biotechnology Product
Second Prix Galien Award for Daiichi Sankyo and AstraZeneca's Enhertu following receipt of the Prix Galien USA Award in 2024 TOKYO, October 30, 2026--(BUSINESS WIRE)--Enhertu® (trastuzumab deruxteca...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.